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Abstract
Background: Early detection of mild cognitive impairment (MCI) and dementia is very important to begin
appropriate treatment promptly and to prevent disease exacerbation. We investigated the screening accuracy of
the Japanese version of Addenbrooke’s Cognitive Examination III (ACE-III) to diagnose MCI and dementia.
Methods: The original ACE-III was translated and adapted to Japanese. It was then administered to a Japanese
population. The Hasegawa Dementia Scale-revised (HDS-R) and Mini-mental State Examination (MMSE) were also
applied to evaluate cognitive dysfunction. In total, 389 subjects (dementia = 178, MCI = 137, controls = 73) took part
in our study.
Results: The optimal ACE-III cut-off scores to detect MCI and dementia were 88/89 (sensitivity 0.77, specificity 0.92)
and 75/76 (sensitivity 0.82, specificity 0.90), respectively. ACE-III was superior to HDS-R and MMSE in the detection of
MCI or dementia. The internal consistency, test-retest reliability, and inter-rater reliability of ACE-III were excellent.
Conclusions: ACE-III is a useful cognitive test to detect MCI and dementia. ACE-III may be widely useful in clinical
practice.
Keywords: Addenbrooke’s cognitive examination, Cognitive screening, Diagnosis dementia, Diagnosis mild
cognitive impairment, Mild cognitive impairment
Background
Early detection of cognitive deterioration in the pro-
dromal stage of dementing diseases is arguably import-
ant in order to initiate curable treatments in the future.
Mild cognitive impairment (MCI) converts to dementia
at a rate of ~ 10% per year [1], but its clinical diagnosis
is a challenge due to the variety and often dynamic na-
ture of symptoms [2]. Nonetheless, a reliable and valid
test to detect MCI in clinical settings has not been
developed [3].
ACE and its revised version (ACE-R) were created as
concise tests for detecting mild cognitive dysfunction [4,
5]. ACE-R has been translated for use in a number of
non-English-speaking countries worldwide and widely
adopted in clinical and research settings [6]. A study at
our facility verified the Japanese version [7]. Despite its
widespread use, ACE-R is relatively weak in several do-
mains, such as repetition, comprehension, and visuospatial
items [2, 6]. Healthy older adults often fail the repetition
item on ACE-R due to poor hearing or a short attention
span [8]. Comprehension items on ACE-R exhibit poor
sensitivity to cognitive impairment because individuals
with cognitive dysfunction often show scores in the nor-
mal range [9]. In addition, some changes in ACE-R fail to
accurately reflect the original ACE. For example, spelling
of the word “WORLD” backwards can be substituted for
subtraction of serial 7 s from 100 in ACE-R, but these two
items are known to present different challenges [10]. Most
importantly, ACE-R included several elements of the
MMSE. Due to copyright issues, it has become difficult to
keep using ACE-R. [11]
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Therefore, the original authors developed a new ver-
sion of ACE, namely ACE-III [6]. ACE-III is also scored
on a total of 100 and contains five cognitive domains.
To date, versions of ACE-III in many different languages
have been validated [12–15], and we recently created a
Japanese version of ACE-III.
In this study, we hypothesized that ACE-III would be
superior to the conventional Hasegawa Dementia
Scale-revised (HDS-R) and Mini-mental State Examin-
ation (MMSE) in detecting MCI and dementia in a Japa-
nese population. Our objective therefore was to (1)
provide detailed normative data for the sub- and total
scores on ACE-III; (2) decide the optimal cut-off scores
of ACE-III to identify MCI or dementia, and compare its
validity with that of MMSE or HDS-R; and (3) evaluate




A total of 389 subjects at the Memory Clinic of Okayama
University Hospital between January 2013 and March
2017 who fulfilled the following criteria were included in
this study (Table 1). All subjects (i) received general phys-
ical and neurological examinations and laboratory testing,
including syphilis serology, plasma vitamin B1, serum vita-
min B12, and thyroid function tests; (ii) took MMSE [16,
17], and HDS-R [18, 19]; and (iii) received magnetic res-
onance imaging (MRI) and/or computed tomography
(CT) of the head. The exclusion criteria were (i) the pres-
ence of delirium or (ii) the existence of psychiatric
diseases.
The profile of each subject (sex, age, years of educa-
tion) was checked. Neuropsychological examinations
were performed by clinical psychologists specialized in
dementia, and the Clinical Dementia Rating (CDR) [20]
score was determined by the chief clinician. When all
examinations had been completed, two or more geriatric
psychiatrists and two or more experienced clinical psy-
chologists conferred, and the clinical diagnosis was
established independent of the performance on ACE-III.
A total of 389 subjects were divided into three groups:
a dementia group (n = 178), an MCI group (n = 137),
and a control group (n = 74).
All patients diagnosed with dementia had a demen-
tia severity of 0.5 (suspicious) or 1 (mild) based on
the CDR. Patients in the dementia group were diag-
nosed with Alzheimer’s disease dementia (ADD; n =
131), dementia with Lewy bodies (DLB; n = 21), be-
havioral variant frontotemporal dementia (bvFTD; n =
9), vascular dementia (VaD; n = 4), and others (n =
13). Patients with ADD were diagnosed with probable
AD according to the criteria formulated by the Na-
tional Institute on Aging-Alzheimer’s Association [21].
Patients with DLB, FTD, or VaD were diagnosed in
accordance with the DLB diagnostic criteria formu-
lated by McKeith et al. [22], the FTDC criteria for
bvFTD [23], and the American Heart Association/
American Stroke Association guidelines for VaD [24],
respectively.
Patients of the MCI group fulfilled the criteria of (1)
concern about a deficit in cognition compared with the
person’s previous level; (2) performance that is lower
than would be expected for the patient’s age and educa-
tional background (CDR score = 0.5) in one or more
cognitive domains; (3) no or minimal disturbance in ac-
tivities of daily living, as established by an interview with
the patient and an informant [25]; and (4) being not
Table 1 Comparison of demographic data, MMSE, HDS-R, ACE-III total and subscores in control, MCI, and dementia groups (n = 389,
standard deviation in parenthesis)
CONTROL MCI DEMENTIA D vs. C D vs. M M vs. C
n = 74 n = 137 n = 178 P values P values P values
Sex, men/women 30/44 71/66 66/112 n.s. * n.s.
Age 72.1 (7.1) 75.3 (8.3) 78.6 (7.2) *** *** *
Education, years 12.9 (2.3) 13.0 (2.7) 12.0 (2.4) * ** n.s.
MMSE, 0–30 28.5 (1.6) 25.5 (2.4) 21.7 (3.3) *** *** ***
HDS-R, 0–30 27.8 (2.2) 23.5 (3.3) 18.7 (3.8) *** *** ***
ACE-III total score, 0–100 93.5 (3.4) 82.7 (7.2) 66.0 (11.4) *** *** ***
Attention and Orientation, 0–18 17.3 (1.1) 16.0 (1.8) 13.0 (2.7) *** *** ***
Memory, 0–26 23.6 (2.2) 16.8 (4.2) 9.8 (4.3) *** *** ***
Fluency, 0–14 11.4 (1.7) 10.2 (2.3) 7.8 (2.7) *** *** **
Language, 0–26 25.6 (0.8) 24.6 (1.7) 21.8 (3.9) *** *** n.s.
Visuospatial, 0–16 15.6 (0.7) 15.1 (1.4) 13.6 (2.9) *** *** n.s.
MMSE Mini-mental State Examination, HDS-R Hasegawa Dementia Scale-revised, ACE-III Addenbrooke’s Cognitive Examination-III, MCI mild cognitive impairment, D
dementia, C control, M MCI, n.s. not significant
*P < 0.05, **P < 0.01, ***P < 0.001. Pairwise comparisons were performed using Bonferroni’s test
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sufficiently functionally and cognitively impaired to meet
the DSM-IV-TR criteria for dementia [26].
Seventy-four subjects with no decline in cognition
compared with their previous level (CDR score = 0) were
used as a control group. None had evidence of organic
dementing disorders or psychiatric diseases, and all had
no impairment in their activities of daily living (ADL)
and instrumental ADL.
Instruments
Like ACE-R, ACE-III is composed of five domains and
each represents a certain cognitive function: (1) orienta-
tion and attention (18 points), (2) memory (26 points),
(3) fluency (14 points), (4) language (26 points), and (5)
visuospatial function (16 points). The highest possible
score on ACE-III is 100 points, and lower scores indicate
worse cognitive functioning.
The differences between ACE-R and ACE-III are as
follows [2, 6]. In the attention domain of ACE-R, serial
subtraction of 7 s from 100 could be replaced by spelling
the word ‘WORLD’ backwards. However, in ACE-III, the
option of spelling ‘WORLD’ backwards was removed,
and only subtraction of serial 7 s from 100 is performed
[2, 6]. In the language domain, the three-step command
was changed to the three single-step commands that in-
crease in syntactical complexity.2 Comprehension of the
written command (‘close your eyes’) was taken out. The
sentence-writing task was modified, and participants are
asked to write two or more sentences on a single topic
for a maximum score of 2 points [2]. The phrase repeti-
tion items were replaced by the repetition of two com-
mon proverbs [2]. Overlapping infinity loops replaced
the intersecting pentagons in the visuospatial section [2].
The memory and fluency domains in ACE-R were not
modified. The translation and modification of ACE-R
into the Japanese version was previously reported in de-
tail [7]. The Japanese version of ACE-III (ACE-III-J) was
modified to reflect the English version of ACE-III.
MMSE is a concise cognition screening test. It in-
cludes a series of items that measure orientation, recall,
language, and visual construction [16, 17]. The full score
of MMSE is 30 points. HDS-R assesses cognitive func-
tion of orientation, memory, attention/calculation,
delayed recall, and verbal fluency [18, 19]. This is a reli-
able and brief instrument to evaluate global cognitive
function. The maximum total possible score is 30 points.
Reliability
Inter-rater reliability was measured by determining the
intraclass correlation coefficient (ICC) of 25 consecutive
patients. Two clinical psychologists assessed subjects at
the same time, and they were blind to each other’s
scores. One of them actively assessed ten patients while
the other passively observed, and their roles were
reversed for the other 15. We evaluated test-retest reli-
ability using the ICC of 26 consecutive patients. The sec-
ond session for test-retest reliability was done four to
eight weeks after the first session. We evaluated the
internal consistency reliability within ACE-III-J using
Cronbach’s coefficient alpha [27].
Statistical analysis
Statistical analyses were performed using the IBM SPSS
Statistics 23.0 software program. A value of P < 0.05 was
accepted as significant. Two groups were compared by
independent sample t-tests. Three groups were com-
pared using one-way analysis of variance, followed by
Bonferroni correction at the time of post hoc analysis. χ2
tests were used for comparison of categorical data (gen-
der). We used a multiple regression analysis to examine
possible associations of the clinical characteristics (gen-
der, age, and years of education) with the total ACE-III
score.
We determined the sensitivity and specificity of
ACE-III, MMSE, and HDS-R using a receiver operating
characteristic (ROC) curve [7]. We used the area under
the curve (AUC) as a scale of each test’s ability to differ-
entiate between groups of participants (dementia vs.
MCI and normal; MCI vs. normal).
In this study, we used StAR software to assess statis-
tical differences between AUCs of the three tests [28].
The most suitable cut-off scores for identifying dementia
and MCI were determined as the scores that led to the
maximal accuracy of classification. Subsequently, posi-
tive predictive values (PPV) and negative predictive
values (NPV) were estimated at different prevalence
rates (5, 10, 20, and 40%) for each optimal cutoff score.
Correlation between the CDR sum of box (CDR SoB)
score and ACE-III scores was evaluated using Spear-
man’s correlation coefficient. A value of P < 0.05 was
accepted as significant.
Results
Clinical characteristics of dementia, MCI, and control
groups
Table 1 shows the clinical characteristics, MMSE scores,
HDS-R scores, and ACE-III-J total and subdomain
scores of dementia, MCI, and control groups.
Age (F (2, 386) = 20.93, P < 0.001) and years of educa-
tion (F (2, 386) = 7.47, P = 0.001) were significantly dif-
ferent between the three groups. The dementia group
was significantly older and less educated than the con-
trol and MCI groups, and the MCI group was older than
the control group. The multiple regression analysis
showed that age (β; standard partial regression coeffi-
cient = − 0.282, P < 0.001) and education (β = 0.129, P <
0.05) had a significant impact on the ACE-III-J score.
When the same analysis was done on the normal
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controls (n = 74), it revealed that only age (β = − 0.266, P
< 0.05) affected ACE-III-J performance significantly.
ACE-III-J total (F (2, 386) = 288.562, P < 0.001), MMSE
(F (2, 386) = 184.793, P < 0.001), and HDS-R (F (2, 386)
= 189.996, P < 0.001) scores were significantly different
between the three groups. On ACE-III-J, scores of all
five subdomains differed significantly among the three
groups. According to the post hoc analysis with Bonfer-
roni correction, the control and MCI groups had higher
scores in all five domains than the dementia group (P <
0.001). The control group had higher scores than the
MCI group in attention/orientation, memory, and flu-
ency domains, but the differences between the two
groups in language and visuospatial scores were not
significant.
Demographics of dementia group (very mild and mild)
The dementia group (n = 178) was subdivided into two
groups, very mild (CDR = 0.5) and mild (CDR = 1), ac-
cording to the CDR score. The clinical characteristics
are shown in Table 2.
There were no significant differences in education or
gender distribution between the groups. The mild de-
mentia group was significantly older than the very mild
dementia group (P < 0.05) and had significantly lower
scores than the very mild dementia group on ACE-III-J,
MMSE, and HDS-R (P < 0.001). On four of the subscores
of the ACE-III-J, excluding the memory score, the mild
dementia group had significantly lower scores than the
very mild dementia group.
Normative data
Normative scores were generated for the ACE-III-J total
and subdomain scores using data of the control group,
based on the mean minus two standard deviations
(lower limits of normal) for three age bands (≤69, 70–
79, and ≥ 80 years old) as well as all age groups, as
shown in Table 3.
Among the three age groups, the number of years of
education differed (F (2, 71) = 5.228, P < 0.01). By post
hoc analysis, the ≤69 age group had more years of edu-
cation than the 70–79 and ≥ 80 age groups (respectively,
P = 0.036 and 0.016).
Among these three age groups, ACE-III-J total scores
(F (2, 71) = 3.857, P < 0.05) and visuospatial subscores (F
(2, 71) = 4.031, P < 0.05) differed. No significant differ-
ences were found between the three groups in the atten-
tion/orientation (F (2, 71) = 0.279, P = 0.757), memory (F
(2, 71) = 1.173, P = 0.315), fluency (F (2, 71) = 1.900 P =
0.157), and language (F (2, 71) = 0.174, P = 0.841) sub-
scores. In the total ACE-III-J score, post hoc analysis
disclosed no significant difference among the three
groups. The scores of the ≤69 age group were signifi-
cantly higher than those of the ≥80 age group (P < 0.05)
in the visuospatial domain.
Diagnostic interpretation
The ROC curves of ACE-III-J, HDS-R, and MMSE for
diagnosing MCI or dementia are shown in Fig. 1 (for
MCI in Fig. 1a, and for dementia in Fig. 1b). The AUCs
of ACE-III-J, HDS-R, and MMSE for diagnosing MCI
were 0.914 (0.876–0.953), 0.859 (0.807–0.912), and 0.838
(0.780–0.896), respectively. The AUC of ACE-III-J was
significantly larger than those of HDS-R and MMSE
(ACE-III-J vs. HDS-R, P < 0.05; ACE-III-J vs. MMSE, P
< 0.01). The most suitable cut-off score of ACE-III-J for
discriminating MCI patients from controls was 88/89
(sensitivity 0.77, specificity 0.92), and those of the
HDS-R and MMSE were 24/25 (sensitivity 0.57, specifi-
city 0.89) and 26/27 (sensitivity 0.61, specificity 0.86), re-
spectively. The PPV and NPV of ACE-III for identifying
MCI at different prevalence rates were 5% (PPV 0.35,
NPV 0.99), 10% (PPV 0.52, NPV 0.97), 20% (PPV 0.72,
NPV 0.94), and 40% (PPV 0.87, NPV 0.86) (Table 4).
The AUCs of ACE-III-J, HDS-R, and MMSE for diag-
nosing dementia were 0.938 (0.915–0.960), 0.881
(0.847–0.915), and 0.881 (0.847–0.914), respectively. The
AUC of ACE-III-J was significantly larger than those of
HDS-R and MMSE (ACE-III-J vs. HDS-R, P < 0.001;
ACE-III-J vs. MMSE, P < 0.001). For discriminating de-
mentia patients from MCI patients and controls, the
most suitable cut-off score of ACE-III-J was 75/76 (sen-
sitivity 0.82 and specificity 0.90), and those of HDS-R
and MMSE were 20/21 (sensitivity 0.67, specificity 0.89)
and 23/24 (sensitivity 0.64, specificity 0.87), respectively.
Table 2 Comparison of demographic data, MMSE, HDS-R, ACE-
III total and subscores in very mild (CDR 0.5) and mild (CDR 1)
dementia groups (n = 178, standard deviation in parenthesis)
VERY MILD MILD P
valuesn = 113 n = 65
Sex, men/women 43/70 23/42 n.s.
Age 77.6 (7.7) 80.4 (6.0) *
Education, years 11.8 (2.3) 12.3 (2.5) n.s.
MMSE, 0–30 22.5 (3.0) 20.2 (3.1) ***
HDS-R, 0–30 19.7 (3.3) 16.9 (4.0) ***
ACE-III total score, 0–100 68.7 (10.2) 61.1 (11.8) ***
Attention and Orientation, 0–18 13.8 (2.4) 11.7 (2.6) ***
Memory, 0–26 10.1 (4.2) 9.1 (4.3) n.s.
Fluency, 0–14 8.2 (2.5) 7.1 (3.0) *
Language, 0–26 22.5 (3.4) 20.5 (4.4) **
Visuospatial, 0–16 14.1 (2.4) 12.7 (3.3) **
MMSE Mini-mental State Examination, HDS-R, Hasegawa Dementia Scale-
revised, ACE-III Addenbrooke’s, Cognitive Examination-III; CDR clinical dementia
rating, n.s. not significant
*P < 0.05, **P < 0.01, ***P < 0.001
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The PPV and NPV of ACE-III for identifying dementia
at different prevalence rates were 5% (PPV 0.30, NPV
0.99), 10% (PPV 0.48, NPV 0.98), 20% (PPV 0.67, NPV
0.95), and 40% (PPV 0.85, NPV 0.88) (Table 4).
Reliability
The inter-rater reliability of ACE-III-J was very good,
with an ICC of 0.996. The test-retest reliability of
ACE-III-J was also very good (ICC = 0.918). The internal
consistency of ACE-III-J was high (Cronbach’s coeffi-
cient α = 0.870).
ACE-III scores and CDR sum of boxes
Spearman’s correlation analysis of the scores of the CDR
SoB and the ACE-III scores revealed that there was a
significant correlation between them (correlation coeffi-
cient = − 0.396, p < 0.001) in MCI patients.
Discussion
The reliability of ACE-III-J was excellent. ACE-III-J was
found to be a sensitive and specific screening test to
diagnose MCI and dementia in a Japanese sample, and it
was better than the MMSE and HDS-R in accuracy for
identifying MCI and dementia. These results suggest
that ACE-III-J is a reliable and valid screening
instrument.
Although ACE-III-J takes slightly longer to perform
than MMSE and HDS-R, it evaluates a broader range of
cognitive functions than MMSE and HDS-R, particularly
in the domains of memory, language, and visuospatial
components [7]. Thus, we consider that ACE-III-J pro-
vides a more useful and precise instrument than MMSE
and HDS-R for diagnosing MCI and dementia. However,
in 19 of the subjects, screening results for dementia are
positive in MMSE but negative in ACE-III. Six of the 19
persons were diagnosed as dementia. Even if a person
takes a score that exceeds the cut-off score in ACE-III, it
is necessary to consider the possibility of dementia if the
MMSE score of the person is below the cut-off score for
dementia in MMSE.
Several non-English versions of the ACE-III have been
reported [12, 14, 15, 29]. The mean scores of controls in
various studies were 95.4 points (mean age 66.1 years,
Table 3 Lower limit of normal (cut-off scores) of ACE-III total and subscores for age bands (< 69, 70–79, > 80 years old) and all age
groups (control mean - 2 standard deviations)
AGE N EDUCATION TOTAL ATTENTION MEMORY FLUENCY LANGUAGE VISUO
(range) (mean, years) (max. 100) (max. 18) (max. 26) (max. 14) (max. 26) (max. 16)
- 69 26 14.0 89 16 20 10 25 16
70–79 39 12.6 87 16 20 8 24 14
80 - 9 11.6 85 15 19 8 24 14
All 74 12.9 87 16 20 8 24 15
ACE-III Addenbrooke’s Cognitive Examination-III, Visuo, visuospatial
Fig. 1 Comparative AUROCs of tests for diagnosis of each condition.
A (upper). ROC curves for discriminating MCI from controls using
ACE-III, HDS-R, and MMSE. B (lower). ROC curves for discriminating
dementia from non-dementia (controls and MCI), using ACE-III, HDS-
R, and MMSE
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education 13.9 years) on the English version [6], 96.7
points (mean age 66.6 years) on the English version [30],
89.4 points (mean age 70.4 years, education 6.2 years) on
the Portuguese version [12], 89.4 points (mean age 65.8
years, education 12.4 years) on the Spanish version [29],
89.3 points (mean age 68.7 years, education 11.5 years)
on the Chinese version [15], and 93.5 points (mean age
72.1 years, education 12.9 years) on the Japanese version.
Age and years of education had significant effects on the
total ACE-III score, as shown in several studies includ-
ing ours [15, 29], and those two factors might explain
the differences in mean scores to some extent. The total
and subscores of the control group of ACE-III-J were al-
most identical to those of the original English version.
The mean scores of ACE-III-J vs. the original ACE-III
were 93.5 vs. 95.4 in total score, 17.4 vs.17.3 in the atten-
tion domain, 25.6 vs. 25.6 in the language domain, and
15.6 vs. 15.6 in the visuospatial domain. The memory
and fluency subscores in the original English version
were not reported in the first paper [6].
The cut-off scores of the original ACE-III scores were
almost identical to those of the original ACE-R [6].
Thus, the Japanese version of ACE-III was equivalent to
the original English version as a cognitive screening in-
strument. The optimal cut-off score for identifying MCI
(88/89) in this study was similar to the original higher
cut-off score (88) for identifying dementia. The cut-off
score for identifying dementia (75/76) in this study was
lower than the original lower cut-off score (82). The ori-
ginal study for ACE-R compared dementia patients with
normal controls rather than MCI patients [5]. In this
study, we set an optimal cut-off score to differentiate de-
mentia patients from MCI patients. The difference in
comparative groups tested to create the cut-off scores of
English and Japanese versions may have caused the dif-
ference in cut-off scores.
The sensitivities reported by other studies in which
the sensitivity of the dementia diagnosis was evaluated
are higher than that (0.82) in this report. In particular,
Elamin et al. reported that the sensitivity for the diagno-
sis of dementia was 0.915, and Wang et al. reported that
the sensitivity was 0.911. However, they calculated the
sensitivity in distinguishing dementia patients from cog-
nitively normal subjects or patients with subjective
memory impairment in previous reports [15, 30]. In this
study, in contrast, we evaluated the sensitivity in distin-
guishing dementia patients from MCI patients and nor-
mal subjects. The difference in the targeted patients
might have caused the difference in sensitivity scores.
One study has reported the ability of ACE-III to dis-
criminate MCI from normal controls. Matias-Guiu et al.
showed that ACE-III scores discriminated between con-
trols and amnestic MCI with high accuracy (AUC, 0.906
by ACE-III memory score) [29]. In our study, the
ACE-III-J score (total score) also accurately discrimi-
nated MCI from controls (AUC, 0.914). The study of
Matias-Guiu et al. detected the difference between
amnestic MCI and normal controls. Therefore, the
ACE-III memory score was thought to be sensitive
enough to discriminate the difference. In this study, the
discrimination between MCI (amnestic and
non-amnestic) and normal controls was evaluated, and
the total score of ACE-III-J was thought to be sensitive
enough to differentiate MCI from normal controls.
Although discrimination of dementia patients from
normal controls was reported by several studies [15, 29],
the discrimination between dementia and MCI patients
was evaluated in only one study [29]. Matias-Guiu et al.
reported that ACE-III scores discriminated MCI and de-
mentia patients with high accuracy (AUC, 0.852 by
ACE-III total score). In this study, ACE-III-J total score
also differentiated dementia patients from those with
MCI with high accuracy (AUC, 0.938).
In the cases diagnosed with MCI in this study, the
higher the CDR SoB scores were, the lower the ACE-III
scores were. Kim et al. reported that the CDR SoB score
Table 4 Sensitivity, specificity and positive predictive values (PPV) at different prevalence rates of optimal cut off ACE-III, HDS-R, and
MMSE scores for identifying MCI and dementia (Values in parentheses represent the respective negative predictive value)
TEST CUT-OFF MCI PPV at different prevalence rates
SCORE SENSITIVITY SPECIFICITY 5% 10% 20% 40%
ACE-III 88/89 0.77 0.92 0.35 (0.99) 0.52 (0.97) 0.72 (0.94) 0.87 (0.86)
HDS-R 24/25 0.57 0.89 0.22 (0.98) 0.37 (0.95) 0.57 (0.89) 0.78 (0.76)
MMSE 26/27 0.61 0.86 0.19 (0.98) 0.33 (0.95) 0.52 (0.90) 0.75 (0.77)
TEST CUT-OFF DEMENTIA PPV at different prevalence rates
SCORE SENSITIVITY SPECIFICITY 5% 10% 20% 40%
ACE-III 75/76 0.82 0.90 0.30 (0.99) 0.48 (0.98) 0.67 (0.95) 0.85 (0.88)
HDS-R 20/21 0.67 0.89 0.24 (0.98) 0.39 (0.96) 0.59 (0.91) 0.80 (0.80)
MMSE 23/24 0.64 0.87 0.21 (0.98) 0.36 (0.96) 0.55 (0.91) 0.77 (0.78)
ACE-III Addenbrooke’s Cognitive Examination-III, HDS-R Hasegawa Dementia Scale-revised, MMSE Mini-mental State Examination
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is useful for predicting the progression to dementia in
amnestic MCI individuals. MCI cases with a low
ACE-III score may be particularly susceptible to devel-
oping dementia in the future [31].
This study has several limitations. First, there were
only a few patients with dementia with Lewy bodies, vas-
cular dementia, or frontotemporal dementia in our
study. Therefore, we were unable to evaluate the differ-
ences in test scores of different dementias. Further study
is needed to clarify whether or not it is possible to differ-
entiate dementing diseases by ACE-III-J scores. Second,
the participants in this study were outpatients at a uni-
versity memory center. Third, we diagnosed dementia
comprehensively including not only MMSE and HDS-R
scores but also total living functions. However, it is un-
deniable that a potential circularity problem may exist.
Thus, the reliability and applicability of ACE-III-J in
community samples need further study.
Conclusions
Regardless of the some limitation, ACE-III-J is an accur-
ate instrument to detect MCI and dementia. ACE-III-J
may be widely useful in clinical practice.
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